The verdict
Our read at a glance.
Whether an anti-catabolic supplement that helps sick and elderly patients does anything for a healthy trained lifter.
- The signal
- The clinical evidence is respectable: HMB reduces markers of muscle protein breakdown and supports lean mass in catabolic and older populations, with registered trials in sarcopenia, hospitalisation, cancer cachexia and rehabilitation, and it appears in clinical nutrition formulations for that reason. In healthy resistance-trained people, the meta-analytic picture is close to null. The reputational damage came from a small number of studies reporting extraordinary changes in lean mass and fat loss in trained subjects - magnitudes that would exceed what anabolic steroids produce - which drew formal methodological criticism and have not been reproduced by independent groups.
- The unknown
- Whether there is a modest real effect in trained people that the noise is hiding, and whether the free-acid form's better kinetics change anything.
- Our read
- Two different products under one name. For an elderly or catabolic patient there is a defensible case. For a healthy trained lifter the honest answer is that the meta-analyses say close to nothing, and the studies that said otherwise reported results that should have been disbelieved on sight.
The mechanism
How it works.
Leucine is the amino acid most strongly associated with switching on muscle protein synthesis, and a small fraction of it - around five per cent - is metabolised to beta-hydroxy-beta-methylbutyrate. HMB appears to act mainly on the other side of the balance sheet: rather than driving synthesis the way leucine does, it suppresses protein breakdown, attenuating the ubiquitin-proteasome pathway and reducing markers of muscle damage. That mechanism predicts exactly the pattern seen in the evidence. In someone who is losing muscle - through illness, immobilisation, ageing or severe energy restriction - reducing breakdown protects tissue and shows up as a measurable benefit. In a healthy, well-fed, training person whose breakdown is not pathologically elevated and whose leucine intake is already adequate from food, there is much less to suppress, and the measured effect approaches zero.
Safety & regulatory boundary
The consequential part.
A supplement, not an approved drug, and safety in trials has been good across populations including older adults. The issue with this compound is evidence quality, not toxicity.
What's next
What we're watching.
Independent replication in trained populations, and continued clinical work in sarcopenia and cachexia where the case is strongest.
Context
Why this is discussed.
It was marketed for years on a handful of trials reporting gains comparable to anabolic drugs, and the collapse of that claim is a useful lesson in reading supplement literature.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · RECRUITING · 2026-08-01
ClinicalTrials.gov · NA · COMPLETED · 2025-06-10
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · NA · COMPLETED · 2023-10-15
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-04-02
ClinicalTrials.gov · NA · RECRUITING · 2026-03-06
ClinicalTrials.gov · NA · RECRUITING · 2025-07-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-03-01
Indexed literature (PubMed)12
Prado CM et al. · J Cachexia Sarcopenia Muscle · 2022
Holeček M · J Cachexia Sarcopenia Muscle · 2017
Rathmacher JA et al. · J Int Soc Sports Nutr · 2025
Lin Z et al. · Front Nutr · 2022
Bideshki MV et al. · J Cachexia Sarcopenia Muscle · 2025
Prado CM et al. · Clin Nutr · 2022
Cohen-Or M et al. · J Nutr Biochem · 2025
Yang C et al. · J Nutr Health Aging · 2023
Slater GJ et al. · Sports Med · 2000
Schakman O et al. · Int J Biochem Cell Biol · 2013
Su H et al. · Front Med (Lausanne) · 2024
He X et al. · Biogerontology · 2025
Keep reading